EPS: As of FY2025 Q1, the actual value is USD -1.41.<h3>Segment Revenue</h3><ul><li>Jasper Therapeutics, Inc. does not have any products approved for sale and has not generated any revenue from product sales.</li></ul><h3>Operational Metrics</h3><ul><li>Net Loss: Jasper Therapeutics, Inc. incurred net losses of $21.2 million for the three months ended March 31, 2025, compared to $13.7 million for the same period in 2024, representing a 55% increase.</li><li>Operating Expenses: Total operating expenses increased by 45% from $15.1 million for the three months ended March 31, 2024, to $21.8 million for the same period in 2025.</li><li>Research and Development Expenses: Increased by 57% from $10.3 million for the three months ended March 31, 2024, to $16.2 million for the same period in 2025.</li><li>General and Administrative Expenses: Increased by 18% from $4.8 million for the three months ended March 31, 2024, to $5.6 million for the same period in 2025.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Negative operating cash flows of $22.8 million for the three months ended March 31, 2025, compared to $15.7 million for the same period in 2024.</li><li>Cash and Cash Equivalents: As of March 31, 2025, Jasper Therapeutics, Inc. had cash and cash equivalents of $48.8 million.</li></ul><h3>Unique Metrics</h3><ul><li>Accumulated Deficit: As of March 31, 2025, Jasper Therapeutics, Inc. had an accumulated deficit of $262.1 million.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: Jasper Therapeutics, Inc. plans to advance product candidates through preclinical studies and clinical trials, procure the manufacture of supplies for preclinical studies and clinical trials, and pursue regulatory approval for product candidates that successfully complete clinical trials.</li><li>Non-Core Business: The company is actively evaluating the potential for briquilimab in additional mast cell driven diseases and intends to become a fully integrated discovery, development, and commercial company in the field of mast cell therapeutics.</li><li>Priority: Management plans to monitor expenses and raise additional capital through a combination of public and private equity, debt financings, strategic alliances, and licensing arrangements.</li></ul>

Jasper Therapeutics - CW26 | 10-Q: FY2025 Q1 EPS: USD -1.41